Trials / Completed
CompletedNCT04589026
A Study Validating the Use of Candin as a Challenge Agent in Healthy Participants - Intervention Specific Appendix 1
A Phase 1, Single Center, Randomized, Controlled Platform Study Validating the Use of Candin As a Challenge Agent in Healthy Volunteers or Patients Given Concomitant Approved Interventions
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 12 (actual)
- Sponsor
- Janssen Research & Development, LLC · Industry
- Sex
- All
- Age
- 18 Years – 55 Years
- Healthy volunteers
- Accepted
Summary
The purpose of this study is to characterize the delayed-type hypersensitivity (DTH) response at the site of Candin intradermal injection in the presence of a targeted immune pathway inhibitor.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Cosentyx | Cosentyx injection will be administered subcutaneously. |
| DRUG | Candin | Candin will be administered interadermally along with NaCl solution. |
Timeline
- Start date
- 2020-10-21
- Primary completion
- 2021-05-06
- Completion
- 2021-05-06
- First posted
- 2020-10-19
- Last updated
- 2025-02-03
Locations
1 site across 1 country: Belgium
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT04589026. Inclusion in this directory is not an endorsement.